Cincinnati Center for Excellence in Molecular Hematology

辛辛那提分子血液学卓越中心

• 批准号: 8509681
• 负责人: YI ZHENG
• 金额: $ 68.35万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8509681
• 关键词: Academic Medical Centers; Affect; Area; Basic Science; Biological Process; Bone Marrow Diseases; Bone Marrow Transplantation; Cancer Center Support Grant; Caring; Cell Adhesion Molecules; Cell Therapy; Cell Volumes; Cells; Cellular biology; Child; Clinical; Clinical Immunology; Clinical Management; Clinical Research; Clinical Trials; Code; Collection; Complement; Complex; Comprehensive Health Care; Development; Disease; Doctor of Philosophy; Environment; Erythrocytes; Erythropoiesis; Experimental Hematology; FDA approved; Faculty; Fanconi' s Anemia; Flow Cytometry; Foundations; Functional disorder; Funding; Future; Genes; Genetic; Genomics; Goals; Grant; Growth; Growth Factor; Hematological Disease; Hematology; Hematopoiesis; Hematopoietic; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Hemoglobinopathies; Home environment; Human; Hypersensitivity; Immune; Immune system; Immunity; Immunobiology; Immunologic Deficiency Syndromes; Immunologics; Immunology; In Vitro; Individual; Inherited; Innovative Therapy; Investments; Lentivirus Vector; Leukocytes; Life; Link; Medical center; Medicine; Methods; Molecular; Molecular Biology; Mouse Strains; Mus; Myelogenous; Myeloid Cells; National Heart, Lung, and Blood Institute; Natural Immunity; North America; Pancytopenia; Participant; Pathogenesis; Pathway interactions; Patients; Pediatric Hospitals; Peer Review; Phase; Physicians; Physiological; Pilot Projects; Pneumonia; Process; Production; Publications; Rare Diseases; Regulation; Research; Research Infrastructure; Research Personnel; Research Support; Retroviridae; Scientist; Services; Sickle Cell; Sickle Cell Anemia; Side; Signal Pathway; Signal Transduction; Societies; Sorting - Cell Movement; Stem cells; Structure; Subfamily lentivirinae; Syndrome; Technology; Therapeutic; Transfusion; Transgenic Organisms; Translating; Translational Research; Transplantation; United States; United States National Institutes of Health; Universities; Viral Vector; Virus; Wiskott-Aldrich Syndrome; assay development; base; cell behavior; cellular transduction; chemokine; clinical care; college; cytokine; design; gene therapy; genetic manipulation; immunohematology; in vivo; inhibitor/antagonist; innovation; member; mouse model; oncology; patient population; pre-clinical; pre-clinical research; preclinical study; programs; rho GTP-Binding Proteins; small molecule; stem; stem cell biology; trait; translational study; vector

The successful application of molecular and cell therapeutics to transplantable hematopoietic cells, including hematopoietic stem cells, holds the promise of life-long cures for inherited diseases of bone marrow-derived cells. The long term goal of the Cincinnati Center of Excellence in Molecular Hematology (CCEMH) is to understand and correct at the molecular level diseases with gene/environmental interactions affecting cells derived from hematopoietic stem cells. We believe that to attain this goal, we must understand basic biological processes that affect lympho-hematopoietic stem cell behavior in vitro and in vivo. We envision this long term goal will be accomplished by inter-disciplinary approaches using state-of-the-art molecular and cell biology methods along with timely and rational use of translational studies in the preclinical and clinical settings. Cincinnati Children's Hospital Medical Center (CCHMC), University of Cincinnati College of Medicine (UC), has developed an intellectual environment that brings together outstanding expertise in virus vector technology, stem cell biology, immune cell biology, basic research in signaling and clinical care in hematology, allergy/immunology and hematopoietic stem cell transplantation. This focus has been greatly strengthened by recruitment of over 50 faculty in these areas in the last 10 years at CCHMC and UC. The areas of basic research are linked by a newly developed and unique Translational Research Initiative, which has facilitated inter-disciplinary interactions and developed an infrastructure that is supporting state-of-the-art trials in cell and gene therapy. Thus, in this application for a new CEMH, we seek to solidify exciting and dramatic growth of research in hematology and related innate immunity/immunology at CCHMC using the shared services and administrative structure of this center grant mechanism. The CCEMH seeks to support a well developed translational research core which complements an outstanding array of basic science cores at CCHMC. These cores are functioning to support innovative research and clinical trials both locally and, in some cases nationally and internationally, in hematology and related immune-based diseases. The relevant cores include a Mouse Xenotransplant/transgenic Core, which maintains specialized mouse strains and provides mouse transplant and transgenic services, a Flow Cytometry Core that includes state-of-the-art hematology flow analysis and sorting capabilities, a Genomics & Genetics Core that support cutting edge genomic analysis of hematologic diseases and normal genetic traits of stem/progenitor cells, and a Translational Core that covers services such as ex vivo manipulation and collection of human cell products, lenti- and retrovirus production, and sophisticated preclinical assay development. Finally, this core grant seeks support for a Pilot/Feasibility program that focuses a highly successful institutional peer-reviewed pilot project initiative into hematologic and related immunologic research and an enhancement program in hosting seminars and annual retreat of the center.

将分子和细胞疗法成功应用于可移植造血细胞（包括造血干细胞），有望终身治愈骨髓源性细胞的遗传性疾病。辛辛那提分子血液学卓越中心（CCEMH）的长期目标是在分子水平上了解和纠正影响造血干细胞来源细胞的基因/环境相互作用疾病。我们认为，要实现这一目标，我们必须了解影响淋巴造血干细胞体外和体内行为的基本生物学过程。我们设想这一长期目标将通过跨学科的方法来实现，使用最先进的分子和细胞生物学方法，沿着及时和合理地使用临床前和临床环境中的转化研究。辛辛那提儿童医院医学中心（CCHMC），辛辛那提大学医学院（UC），已经开发了一个智力环境，汇集了病毒载体技术，干细胞生物学，免疫细胞生物学，信号基础研究和血液学，过敏/免疫学和造血干细胞移植临床护理的杰出专业知识。在过去的10年里，CCHMC和UC在这些领域招募了50多名教师，大大加强了这一重点。基础研究领域通过新开发的独特的转化研究计划联系在一起，该计划促进了跨学科的互动，并开发了支持细胞和基因治疗最先进试验的基础设施。因此，在新CEMH的申请中，我们寻求使用该中心拨款机制的共享服务和行政结构来巩固CCHMC血液学和相关先天免疫/免疫学研究的令人兴奋和急剧增长。CCEMH旨在支持一个发展良好的转化研究核心，补充CCHMC基础科学核心的杰出阵列。这些核心正在发挥作用，以支持创新的研究和临床试验，无论是在当地，在某些情况下，国家和国际上，在血液学和相关的免疫性疾病。相关核心包括小鼠异种移植/转基因核心，其保持专门的小鼠品系并提供小鼠移植和转基因服务，流式细胞术核心，其包括最先进的血液学流动分析和分选能力，基因组学和遗传学核心，其支持血液病的尖端基因组分析和干细胞/祖细胞的正常遗传性状，和一个翻译核心，涵盖服务，如离体操作和收集人类细胞产品，慢病毒和逆转录病毒的生产，以及复杂的临床前检测开发。最后，该核心赠款寻求对试点/可行性计划的支持，该计划将一个非常成功的机构同行评审试点项目倡议集中在血液学和相关免疫学研究以及举办研讨会和中心年度务虚会的增强计划上。